Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #242564 on Biotech Values
DewDiligence
05/20/22 9:16 PM
#242565 RE: dewophile #242564
Is it accepted dogma that T causes ovarian CA in trans males?
05/27/22 1:38 PM
#242634 RE: dewophile #242564
Mercy BioAnalytics, Inc., a pioneer in extracellular vesicle-based liquid biopsies for the early detection of cancer, today announced that the Mercy Halo Ovarian Cancer (OC) assay substantially outperformed CA125 when distinguishing patients with early-stage high-grade serious ovarian cancer (HGSOC) from women with benign conditions in a new study to be presented next week at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting. The assay uses a novel method of analyzing biomarkers based on individual extracellular vesicles (EVs).